.
BLOCK LISTING SIX MONTHLY RETURN
May 24, 2010 - Shire plc (LSE: SHP, NASDAQ: SHPGY)
Name of applicant:                     Shire plc

Name of scheme:                        1996 Executive Share Option Scheme

Period of return:            From:     23 November 2009 To:   22 May 2010

Balance of unallotted securities under 81,000
scheme(s) from previous return:

Plus: The amount by which the block    Nil
scheme(s) has been increased since the
date of the last return (if any
increase has been applied for):

Less: Number of securities issued/     Nil
allotted under scheme(s) during period
(see LR3.5.7G):

Equals: Balance under scheme(s) not    81,000
yet issued/allotted at end of period:
Name of applicant:                     Shire plc

Name of scheme:                        2000 Executive Share Option Scheme

Period of return:            From:     23 November 2009 To:   22 May 2010

Balance of unallotted securities under 4,881,959
scheme(s) from previous return:

Plus: The amount by which the block    Nil
scheme(s) has been increased since the
date of the last return (if any
increase has been applied for):

Less: Number of securities issued/     990,762
allotted under scheme(s) during period
(see LR3.5.7G):

Equals: Balance under scheme(s) not    3,891,197
yet issued/allotted at end of period:
Name of applicant:                     Shire plc

Name of scheme:                        Shire Sharesave Scheme

Period of return:            From:     23 November 2009 To:   22 May 2010

Balance of unallotted securities under 32,341
scheme(s) from previous return:

Plus: The amount by which the block    Nil
scheme(s) has been increased since the
date of the last return (if any
increase has been applied for):

Less: Number of securities issued/     26,949
allotted under scheme(s) during period
(see LR3.5.7G):

Equals: Balance under scheme(s) not    5,392
yet issued/allotted at end of period:
Name of applicant:                     Shire plc

Name of scheme:                        Biochem Pharma Stock Option Plan

Period of return:            From:     23 November 2009 To:   22 May 2010

Balance of unallotted securities under 8,999
scheme(s) from previous return:

Plus: The amount by which the block    Nil
scheme(s) has been increased since the
date of the last return (if any
increase has been applied for):

Less: Number of securities issued/     3,640
allotted under scheme(s) during period
(see LR3.5.7G):

Equals: Balance under scheme(s) not    5,359
yet issued/allotted at end of period:
Name of contact:                        Tony Guthrie, Deputy Company Secretary

Address of contact:                     Hampshire International Business Park

                                        Basingstoke, Hampshire, RG24 8EP

Telephone number of contact:            01256 894754
For further information please contact:
Investor Relations Cléa Rosenfeld (Rest of the World)    +44 1256 894 160

                   Eric Rojas (North America)            +1 781 482 0999
Notes to editors
SHIRE PLC
Shire's strategic goal is to become the leading specialty biopharmaceutical
company that focuses on meeting the needs of the specialist physician. Shire
focuses its business on attention deficit hyperactivity disorder (ADHD), human
genetic therapies (HGT) and gastrointestinal (GI) diseases as well as
opportunities in other therapeutic areas to the extent they arise through
acquisitions. Shire's in-licensing, merger and acquisition efforts are focused
on products in specialist markets with strong intellectual property protection
and global rights. Shire believes that a carefully selected and balanced
portfolio of products with strategically aligned and relatively small-scale
sales forces will deliver strong results.
For further information on Shire, please visit the Company's website:
www.shire.com.
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
END